CSBRHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Champions Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (87): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (14): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CSBR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Mar 2025 | Craig-Hallum | Maintains | Buy | $8.00 → $12 |
| 12 Dec 2024 | Craig-Hallum | Maintains | Buy | — |
| 12 Sept 2024 | Craig-Hallum | Upgrade | Buy | — |
| 13 Mar 2024 | Craig-Hallum | Downgrade | Hold | — |
| 22 Sept 2023 | Roth MKM | Maintains | Buy | — |
| 15 Mar 2021 | Roth Capital | Maintains | Buy | — |
| 18 Nov 2019 | Benchmark | Initiates | Speculative Buy | — |
| 20 Sept 2019 | Roth Capital | Initiates | Buy | — |
| 24 July 2019 | Janney Capital | Downgrade | Neutral | — |
| 24 July 2019 | Janney Montgomery Scott | Downgrade | Neutral | — |
| 17 July 2018 | Craig-Hallum | Initiates | Buy | — |
| 15 May 2018 | Dawson James | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CSBR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 22% of US stocks
Cheaper than 67% of US stocks
Cheaper than 6% of US stocks
Cheaper than 1% of US stocks
Higher than 57% of US stocks
Higher than 50% of US stocks
Higher than 63% of US stocks
Higher than 29% of US stocks
Higher than 28% of US stocks
Higher than 27% of US stocks
Higher than 36% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Champions Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Champions Oncology reported fourth-quarter fiscal 2026 growth with revenue gains, margin improvement, and progress from operational initiatives, though CSBR stock dipped following the earnings announcement.
Why it matters — For CSBR watchers, the results show record revenue growth and operational progress even as the market reacted negatively in the short term.
Seeking Alpha published the transcript of Champions Oncology, Inc.'s Q4 2026 earnings call.
Why it matters — The transcript provides CSBR investors with management's detailed commentary on the company's fourth-quarter financial results and outlook.
Champions Oncology reported record revenue for fiscal 2026 and achieved positive adjusted EBITDA in all four quarters. Growth came from its Translational Oncology Solutions services business and its push to internalize radiopharmaceutical work.
Why it matters — A CSBR watcher would care because the company delivered record revenue and sustained profitability across every quarter, signaling strong operational momentum.
Champions Oncology reported record annual revenue of $59.4 million for fiscal year 2026, along with fourth-quarter revenue of $13.8 million and positive adjusted EBITDA for the fourth consecutive quarter.
Why it matters — The company achieved its highest-ever annual revenue while sustaining positive adjusted EBITDA throughout the fiscal year, indicating steady financial performance and execution on strategic priorities.
Of the 1 analysts covering Champions Oncology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Champions Oncology, Inc. 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Champions Oncology, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (87 of 100).
No analyst covering Champions Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSBR are extrapolating price history, which says nothing about the business.
Champions Oncology, Inc. returned -31.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology.
The most recent item we track (Zacks Investment Research, 30 July 2026): "CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push". Champions Oncology reported fourth-quarter fiscal 2026 growth with revenue gains, margin improvement, and progress from operational initiatives, though CSBR stock dipped following the earnings announcement.
Champions Oncology, Inc. operates as a biotechnology company with a core focus on developing advanced technologies and research models to enhance drug discovery and therapeutic applications in oncology. The primary function of Champions Oncology is to provide personalized solutions that support pharmaceutical companies and research institutions in understanding the complex biology of cancer. This is achieved through their pioneering ex vivo and in vivo platforms, primarily the TumorGraft Technology, which enables the testing of cancer therapies on live patient-derived tumor cells in a controlled environment. Champions Oncology plays a critical role in the pharmaceutical industry by offering predictive insights that can accelerate the development pipeline and potential success of oncology drugs. This service is crucial for researchers targeting various cancer types as they seek to understand treatment responses and develop targeted therapies. The company's offerings have significant implications in advancing precision medicine and optimizing clinical trial design, making it a valued partner for innovative cancer research initiatives globally.
CEO Mr. Robert Brainin · 214 employees · United States · https://www.championsoncology.com